FAQ: How Does Weight Reduction Impact PsA Outcomes?

In this educational video, Shannon Ghizzoni, a physician assistant at Columbus Arthritis Center, explores the impact of weight reduction on disease activity and treatment outcomes in Psoriatic Arthritis. This discussion highlights the strong connection between obesity—particularly visceral fat—and increased inflammation in patients with psoriatic arthritis and psoriasis. Learn how excess adipose tissue contributes to a pro-inflammatory state by elevating cytokines such as Tumor Necrosis Factor alpha, Interleukin-6, and Interleukin-17—key drivers of joint inflammation, enthesitis, and skin manifestations. The video also explains how obesity may reduce the effectiveness of biologic therapies like TNF inhibitors, making weight management a critical component of comprehensive care. Additionally, this module reviews the link between psoriatic arthritis and Metabolic Syndrome, emphasizing the role of central obesity and metabolic dysfunction in worsening disease burden. A featured 2019 clinical study demonstrates that significant weight loss—achieved through a very low-calorie diet—led to meaningful improvements in disease activity, including reduced joint counts, lower CRP levels, improved psoriasis severity, and enhanced physical function. Notably, patients achieving minimal disease activity nearly doubled, with sustained benefits observed up to 24 months. This video underscores the importance of integrating weight reduction strategies alongside pharmacologic therapy to optimize outcomes in psoriatic arthritis. Discover how lifestyle interventions can create a synergistic effect with disease-modifying treatments to improve long-term patient outcomes. For more expert-driven rheumatology education, visit the RhAPP platform, explore the Content Rheum, or download the RhAPP ACE App for on-the-go learning. #PsoriaticArthritis #Rheumatology #ObesityAndInflammation #APPeducation #BiologicTherapy #TNFinhibitors #MetabolicSyndrome #ContentRheum #RhAPP